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Background: Rare diseases pose many research challenges specific to their scarcity. Advances in potential therapies
have made it more important than ever to be able to adequately identify not only patients with particular
genotypes (via patient registries) but also the medical professionals who provide care for them at particular
specialist centres of expertise and who may be competent to participate in trials. Work within the neuromuscular
field provides an example of how this may be achieved.
Methods: This paper describes the development of the TREAT-NMD Care and Trial Site Registry (CTSR), an initiative
of an EU-funded Network of Excellence, and its utility in providing an infrastructure for clinical trial feasibility,
recruitment, and other studies.
Results: 285 CTSR-registered centres, reporting 35,495 neuromuscular patients, are described alongside an analysis
of their provision for DMD. Site characteristics vary by country: the average number of DMD patients seen per site
in the United States (96) is more than in Germany (25), and paediatric/adult breakdown is also markedly distinct.
Over 70% of sites have previous trial experience, with a majority including a Clinical Trials Unit. Most sites also have
MLPA diagnostic capability and access to a range of medical specialists. However, in the three countries reporting
most sites (US, the UK and Germany), few had access to all core DMD specialists internally. Over 60% of sites did
not report any form of transition arrangement.
Conclusions: Registries of care and trial sites have significant utility for research into rare conditions such as
neuromuscular diseases, demonstrated by the significant engagement by industry and other researchers with the
CTSR. We suggest that this approach may be applicable to other fields needing to identify centres of expertise with
the potential to carry out clinical research and engage in clinical trials. Such registries also lend themselves to the
developing context of European Reference Networks (ERNs), which seek to build networks of centres of expertise
which fit specific criteria, and which may themselves aid the sustainability of such registries. This is particularly the
case given the utility of registries such as the CTSR in enabling networks of best-practice care centres.
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Table 1 Simplified description of data captured in
TREAT-NMD CTSR
Patient cohort Patients stratified by disease and age range
(currently 10 NMDs including subtypes e.g.
SMA I, II, III).
Diagnostic tools as most appropriate for
each condition.
Care settings Availability of specialists and services
in-centre.
Arrangements for transition care.
Availability of particular pulmonary, cardiac,
muscle and bone function tests in-centre.
Availability of particular physiotherapy
facilities and equipment in-centre.
Availability of emergency care in-centre.
Experience of centre in conducting skeletal
muscle biopsies.
Research and
education
Extent of use of centre data in research,
research funding arrangements, and papers
authored by staff at centre
Extent to which staff at centre have been
involved in providing training at national
and international levels
Clinical trial
infrastructure
Available personnel (e.g. Study Nurses,
Physiotherapists, Pharmacists)
Previous experience (e.g. details of past
participation in Phase I, II, III, IV clinical trials)
Availability and details of equipment
(e.g. refrigerators, IT support)
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Rare diseases, those affecting fewer than 5 in 10,000 EU
citizens, pose a range of challenges to researchers [1].
Identifying sufficient patients with a given condition, let
alone a specific genotype, to conduct meaningful clinical
trials, natural history studies or health care research is
difficult in small populations. Limited patient cohorts
have been a barrier to the development of new therapies
for rare diseases. Orphan drugs legislation, designed to
encourage investment in the field, has had a positive im-
pact with an unprecedented number of clinical trials ini-
tiated for rare diseases. However, it has also exposed a
lack of trial readiness in many rare disease communities,
with an increasing need to identify both patients who
might participate in studies and sites with sufficient ex-
perience to take part in trials.
The requirement to improve trial readiness for the
neuromuscular field was addressed via infrastructures de-
veloped by the EU FP6-funded TREAT-NMD network of
excellence. Within this network, a series of patient regis-
tries, frequently established and run in collaboration with
patient organisations, have established a resource for the
identification of patients with specific genotypes and diag-
noses (Duchenne Muscular Dystrophy, Spinal Muscular
Atrophy and other neuromuscular diseases) [2]. Other
disease areas have taken a similar approach with the most
recent Orphanet Report “Disease Registries in Europe”
cataloguing 588 registries [3,4].
Patient identification is merely part of the challenge of
establishing clinical trials in rare diseases. Only a limited
number of clinics exist with experience in caring for
patients with rare diseases and conducting research in
the field, and those for any specific disease are often few
and far between. Such issues have spurred the develop-
ment and activities of specialised professional networks
for a variety of rare and more common conditions,
including the Parkinson’s Study Group, the European
Cystic Fibrosis Society, and the European Huntington’s
Disease Network [5-7].
Neuromuscular diseases form a group of conditions
often treated by the same professionals. Specialist neuro-
muscular clinics caring for patients with Duchenne mus-
cular dystrophy (DMD) will often also see patients with
Spinal Muscular Atrophy (SMA), Congenital Muscular
Dystrophies (CMDs) and sometimes other conditions
such as Charcot-Marie-Tooth disease (CMT) and Limb-
Girdle Muscular Dystrophies (LGMDs) [8]. Those wor-
king in such clinics are thus likely to possess specialist
skills and expertise with applicability to a range of neu-
romuscular conditions. However, identifying the loca-
tions of such sites and their capabilities has hitherto
proved difficult.
We describe the development and utilisation of an on-
line registry of care and trial sites for neuromusculardisorders that addresses these challenges, the TREAT-
NMD Care and Trial Site Registry (CTSR), operational
since December 2007.
Methods
The CTSR is an online self-registration database for neu-
romuscular centres hosted by the University Medical
Center Freiburg, Germany. Its initial aim was to enable
clinical trial feasibility enquiries, but it has since been used
for a range of feasibility, trial, and research enquiries.
The CTSR technical platform comprises a Java web
application running on a MySQL database accessed via a
secure web server. This allows swift self-registration and
update of information by any internet-connected centre,
regardless of geographic location. The application is
designed in such a way to permit future extension.
CTSR questions were chosen via expert consensus
within the TREAT-NMD network, and are based on typi-
cal industry feasibility enquiries and EUCERD recommen-
dations [9]. They are wide-ranging across four broad
categories: Patient Cohort, Care Settings, Research and
Education, and Clinical Trial Infrastructure (Table 1). Fur-
ther detail is available on the TREAT-NMD website [2].
Two additional sections capture project-specific data:
a questionnaire on DMD care provision, used by the
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7 European countries; and a series of qualitative ques-
tions for UK neuromuscular sites developed in conjunc-
tion with the Muscular Dystrophy Campaign [10,11].
Centres register for the CTSR via the TREAT-NMD
website. All requests are manually curated to ensure the
validity of new registrants. A user agreement must be
signed and registrants can define the purposes for which
their data may be used. Once registered, data is entered
into online forms organised by the topic categories indi-
cated above. Sites are recruited globally by a variety of
means, particularly via professional networks, including
TREAT-NMD and its associated communications infra-
structure, such as the TREAT-NMD newsletter which is
distributed monthly to 3,500 recipients. The CTSR is
also frequently publicised at conferences and meetings,
and through societies with a neuromuscular focus. In a
country-specific approach, accredited neuromuscular
centres were approached individually through key con-
tacts where available.
As part of the user agreement, sites are asked to indicate
whether their data might be forwarded to third parties
[12]. A typical enquiry is initiated by an approach of an
academic institution or a private company to the TREAT-
NMD Secretariat at Newcastle University. A preliminary
form records broad enquiry parameters, including time-
lines, target disease and genotypic criteria. In some cases,
the enquiry may utilise the TREAT-NMD Global Database
(an international federated database of National Patient
Registries) in addition to the CTSR. Once an enquiry goes
ahead, the CTSR team generates the dataset defined by
the terms of the enquiry, and creates a report containing
the requested information from all sites that have agreed
to forward their data. After each enquiry all sites areFigure 1 Map showing number of sites registered in the CTSR by couinformed about the enquiry and the data that has been
provided. The requesting party receives relevant informa-
tion to answer their enquiry, but does not get uncon-
trolled access to the full CTSR database.
Results
Sites and patient cohort
285 centres in 42 countries are registered in the CTSR,
distributed according to Figure 1. These are characterised
by country in Table 2. The three countries with the largest
number of registered centres are Germany (60), the UK
(41), and the United States (38), totalling 48.8% of sites.
This reflects the initial focus of TREAT-NMD on Europe
with close US collaboration, though the presence of regis-
tered sites worldwide (including in Japan, Australia, and
South America) also demonstrates the evolution of the
network into the TREAT-NMD Alliance with a global
governance structure.
The 285 centres reported a total of 35,495 patients
across 10 diseases (distinguishing between SMA Type I,
Type II, and Type III) with the most commonly reported
being DMD (10,387 patients, 29% of overall cohort)
followed by Myotonic Dystrophy Type I (DM1, 6,043 pa-
tients, 17% of overall cohort) and SMA (5,062 patients,
14% of overall cohort). A breakdown of the CTSR cohort
by disease and paediatric/adult status is provided in
Table 3.
Figures 2, 3, and 4 show the relative numbers of pa-
tients with different neuromuscular conditions in the
CTSR. The prominence of DMD, particularly in the
paediatric cohort, is expected as this disease is the most
common form of childhood muscular dystrophy. In the
adult cohort, the increased prominence of primarily
adult-onset conditions (particularly Myotonic Dystrophy,ntry.
Table 2 CTSR site distribution by country, by total
number of patients per country
Country Sites Total NMD
patients
Avg #
patients
per site
Total DMD
patients
United States 38 7495 197 2777
United Kingdom 41 5765 141 1514
Italy 19 4408 232 795
Germany 60 3909 65 1127
France 20 2206 110 373
Denmark 3 1356 452 186
Canada 10 1008 101 458
Belgium 3 875 292 219
Japan 3 784 261 230
Australia 8 764 96 426
Russia 4 737 184 206
Netherlands 6 691 115 152
Poland 4 628 157 166
Turkey 3 620 207 215
Spain 6 529 88 102
Countries reporting
100–500 NM patients*
36 3130 36 1171
Countries reporting
<100 NM patients**
21 590 21 270
Totals 285 35495 125 10387
*Austria, Brazil, Bulgaria, China, Czech Republic, Hungary, India, Israel, Serbia,
Sweden, Switzerland, Ukraine.
**Algeria, Argentina, Chile, Croatia, Finland, Indonesia, Lithuania, Macedonia,
Moldova, New Zealand, Norway, Pakistan, Portugal, Romania, Slovenia.
Table 3 Patient cohort by disease and age
<18 18+ Total
DMD 8184 2203 10387
BMD 1301 1570 2871
Subtotal B/DMD 9485 3773 13258
SMA I 758 42 800
SMA II 1989 487 2476
SMA III 890 896 1786
Subtotal SMA 3637 1425 5062
LGMD 1630 3798 5428
CMD 918 221 1139
CM 947 418 1365
FSHD 586 2614 3200
DM1 1325 4718 6043
Subtotal Other 5406 11769 17175
Total 18528 16967 35495
Figure 2 Overall patient cohort of CTSR.
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Girdle Muscular Dystrophies) is apparent. We focus pri-
marily on DMD in the following analysis.
Table 4 provides details of the demographics of the
DMD population represented in the CTSR. The three
countries with the largest number of DMD patients in
the CTSR – the United States, United Kingdom and
Germany – are the same as those with the largest num-
ber of sites in the CTSR, and the proportion of adult to
paediatric DMD patients is broadly similar (27.6%, 24.8%
and 27.1% respectively). Sites in these three countries re-
port 5,418 DMD patients, about half (52.2%) of the over-
all DMD cohort (4,277 of 8,184 or 52.3% of adults; 1,141
of 2,203 or 51.8% of children).
Differences are apparent between countries in the size
of individual centres, particularly between those focusing
on adults and paediatric patients. Considering only those
specialist centres that report seeing DMD patients, the
average number of DMD patients at each such centre in
the United States (96) is almost double that in the UK
(52), which in turn is double that in Germany (25). Dispa-
rities in centre size are noted in other countries too: the
average number of DMD patients in France (27) is com-
parable to that Germany, while Italy (53) and Canada (51)
are more similar to the UK.
There are also differences with respect to breakdown
and provision of paediatric and adult care for DMD. In
the United States, 28 of 29 centres report treating both
paediatric and adult patients: only one is a purely paedi-
atric centre for DMD and none are specialist adult cen-
tres. Many of these may be paediatric centres who
continue to provide care to patients as adults. This is in
contrast to the UK and Germany, where sites are split
Figure 3 Paediatric patient cohort of CTSR.
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adult, or both paediatric and adult patients. Further char-
acterisation of the sites in each country is provided in
Table 5. This shows the characteristics of registered
neuromuscular sites treating DMD patients, ordered by
the average size of each site in each country. It is clear that
in those countries where sites are fairly large (significantly
more than 50 DMD patients per site on average), there are
relatively few sites in each country. The exception to this
is the United States, where there are a both a large number
of sites and a large average DMD population per site.Figure 4 Adult patient cohort of CTSR.Table 6 provides characteristics of “adult-only” sites
that see DMD patients in the three countries where
there is more than one such site: the United Kingdom,
Germany and France (seven such sites in each country).
The average number of patients seen at these adult-only
sites is low: 8, 3, and 18 respectively, which is much
lower than the average number of DMD patients seen at
all sites in each country (29, 46 and 24). Again, one ob-
serves striking differences in character of neuromuscular
sites between different countries.
Utility
CTSR data on neuromuscular sites and their patient
cohort helps to plan clinical trials in small populations.
A CTSR enquiry – particularly when combined with an
enquiry of the relevant National Patient Registries, as
shown in Figure 5 (data from 2012) – permits the identi-
fication of the most effective locations for clinical trial
centres via clusters of patients and sites with particular
attributes.
Site attributes
The CTSR holds data on a range of site attributes, which
have wide applicability and utility to researchers. These
include questions related to clinical trial experience and
capabilities, which enables the identification of sites with
particular expertise and equipment. Questions in the
CTSR were developed mindful of the wider context
of evolving criteria for the designation of Centres of
Expertise for Rare Diseases in European Member States
as published by EUCERD [9]. A discussion of a selection
of key site attributes is provided below.
Clinical research and trials
Trial and good clinical practice experience
Table 7 shows several variables associated with the ex-
perience of centres in conducting clinical trials. Answers
to these questions are not restricted to neuromuscular
trials, but could cover all clinical trial experience.
77.0% of reporting sites are familiar with Good Clinical
Practice, whilst just over half (52.5%) have a Clinical
Trials Unit available. Overall, the majority of reporting
sites (72.2%) have some previous clinical trial experience.
Of those providing a more detailed breakdown of their
experience, relatively few have taken part in Phase I
trials (17.2%) and Phase IV trials (21.8%), while more
have taken part in Phase II (43.5%) and Phase III (39.3%)
trials. This is most likely because relatively few sites are
required for Phase I trials, while Phase II/III trials often
take place at the same centres. In the neuromuscular
field, few drugs have received marketing authorisation
and the number of Phase IV trials is still relatively low,
but will require many sites across different countries to
reach their recruitment targets.
Table 4 Demographics of DMD population represented in the CTSR
Country Sites
reporting
DMD
patients
DMD
patients
<18
DMD
patients
18+
Total
DMD
patients
Avg <18
pats/DMD
site
Avg 18+
pats/DMD
site
Avg pats/
DMD site
Sites
reporting
only DMD
Pats <18
Sites
reporting
only DMD
Pats 18+
Sites
reporting
patients both
<18 and 18+
United States 29 2177 600 2777 75 21 96 1 0 28
United Kingdom 29 1213 301 1514 42 10 52 8 7 14
Germany 46 887 240 1127 19 5 25 22 7 17
Italy 15 557 238 795 37 16 53 4 0 11
Canada 9 387 71 458 43 8 51 1 0 8
Australia 3 407 19 426 136 6 142 1 0 2
France 14 159 214 373 11 15 27 1 7 6
Countries
reporting between
100–250 DMD
patients*
41 1798 442 2240 61 20 81 15 2 24
Countries
reporting less
than 100 DMD
patients**
22 599 78 677 27 3 30 10 0 12
Total 208 8184 2203 10387 39 9 48 63 23 122
*Belgium, Czech Republic, Denmark, Hungary, India, Israel, Japan, Netherlands, Poland, Russia, Spain, Switzerland, Turkey.
**Austria, Brazil, Bulgaria, Chile, China, Croatia, Finland, Indonesia, Moldova, Norway, Pakistan, Portugal, Romania, Serbia, Slovenia, Sweden, Ukraine.
Table 5 Characteristics of CTSR sites seeing DMD patients
Country Sites reporting
DMD patients
Total DMD
patients
Minimum number of DMD
patients per site
Maximum number of DMD
patients per site
Avg pats/
DMD site
Japan 1 230 230 230 230
Turkey 1 215 215 215 215
Australia 3 426 51 205 142
Israel 1 109 109 109 109
United States 29 2777 12 398 96
India 2 183 77 106 92
Pakistan 1 80 80 80 80
Belgium 3 219 33 104 73
Russia 3 206 44 95 69
Denmark 3 186 10 160 62
Czech Republic 3 163 10 110 54
Italy 15 795 8 187 53
United Kingdom 29 1514 3 252 52
Canada 9 458 18 155 51
Austria 1 50 50 50 50
Countries reporting a mean of
20–49 DMD patients per site*
91 2594 1 208 29
Countries reporting a mean of <20
DMD patients per site**
13 182 44 96 14
*Brazil, Bulgaria, China, France, Germany, Hungary, Moldova, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Spain, Sweden.
**Chile, Croatia, Finland, Indonesia, Slovenia, Switzerland, Ukraine.
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Table 6 Characteristics of sites seeing only adult DMD patients (in countries with >1 such site)
Country Sites reporting
DMD patients
Sites reporting ONLY
DMD pats <18
Sites reporting
ONLY DMD
pats 18+
Sites reporting
patients both <18
and 18+
Avg patients per site
seeing only 18+
Avg pats/
DMD site
United
Kingdom
29 8 7 14 8 52
Germany 46 22 7 17 3 25
France 14 1 7 6 18 27
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Diagnostic techniques
Swift and accurate diagnosis is a very important aspect
of good care for neuromuscular conditions, and enables
genetic counselling for the family. For DMD, Multiplex
ligation-dependent probe amplification (MLPA) is the
minimum capability recommended in international con-
sensus care standards [13]. This is available and funded
in 149 (70.3%) of 212 reporting sites, with the more
advanced ability to detect point mutations available and
funded at 137 (64.6%) of these sites (Table 8).
Availability of medical specialists
Neuromuscular diseases often require the expertise of a
team of medical specialists with a range of expertise. The
nature of such a multidisciplinary team, co-ordinated by
an expert in the disease, is described as applied to DMD
by Bushby et al. [13]. The majority of sites have coreFigure 5 Maps demonstrating utility of combined CTSR and National
from German/Austrian Patient Registries and CTSR to show location of DM
showing only Exon 51-skippable DMD patients (green dots) under the care
clinical trial (within 2 hours travel time, blue circles).specialities available internally, although this availability
varies depending on speciality (Tables 9 and 10).
In the three countries with the most sites in the CTSR,
relatively few sites reporting DMD patients had all core
specialists available internally, via a team member, or via
joint clinics: 15 of 46 (32.6%) in Germany, 8 of 29
(27.6%) in the UK, and 5 of 29 in the US (17.2%). Where
this is the case, many instead refer to relevant local
provision, serving to organise care which is delivered by
other providers: 40 of 46 (87.0%) in Germany, 22 of 29
(75.9%) in the UK, and 12 of 29 in the US (41.4%).
Again, differences in availability of specialists highlight
differences in care organisation between countries.
Transition care
For conditions with childhood onset such as DMD, tran-
sition from paediatric to adult care can be challenging,
but it is also crucial as more children with the conditionPatient Registry data for recruitment. Left, map combining data
D patients (blue dots) in relation to CTSR sites (yellow dots). Right, map
of two CTSR sites (red circles) and extended recruitment area for
Table 7 Trial and GCP experience
Trial and good clinical practice
Familiarity with good
clinical practice
Availability
of a clinical
trials unit
Previous trial
experience
Trial phase I
experience
Trial phase II
experience
Trial phase III
experience
Trial phase IV
experience
Currently
participating
in a trial
Yes 188 124 177 49 124 112 62 144
No 56 112 68 236 161 173 223 101
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arrangements of sites in the CTSR. It is notable that a
majority (62.8%) of sites do not have any form of transi-
tional arrangement, a finding which lends support to
patient experiences described in other studies such as
that by Abbot et al. [14].
Examples of use of the CTSR
The CTSR had been used for eight industry enquiries by
May 2013 (Table 12), as well as four academic enquiries.
Feasibility enquiry
Industry and academic enquiries were used to support
drug development plans and to preselect potential trial
sites for clinical research. The combined use of patient
registry and CTSR data often proved especially helpful
to assess feasibility of clinical trials in rare NMDs. For
the FOR-DMD steroid trial and other investigator ini-
tiated trials the CTSR was used to collect relevant feasi-
bility information from all participating sites.
CARE-NMD
CARE-NMD, a three-year EU funded project to improve
access to best-practice care for DMD across 7 EU coun-
tries (Bulgaria, the Czech Republic, Denmark, Germany,
Hungary, Poland and the United Kingdom) used the
CTSR in several capacities [11]. These included the
identification of neuromuscular sites, distribution of pro-
fessional questionnaires, and the supplementation of
existing knowledge from national networks such as the
North Star Clinical Network in the UK [15]. The project
demonstrated the flexibility of this web-based platform,
extending the CTSR with additional data fields. A series
of questions relating to care provision for DMD were
developed based on published international consensus
care standards, and integrated with the CTSR [13,16].Table 8 Techniques available for the diagnosis of DMD and S
Availability of specific d
DMD
Limited deletion MLPA Point mutation
Available, funded 176 149 137
Available, not funded 35 42 51
Not available 13 21 33
*Availability includes in-house as well as external genetic testing.In the United Kingdom parallel initiatives were under-
way to improve knowledge of the state of neuromuscular
care. These included audits of care provision by the
Muscular Dystrophy Campaign and the British Myology
Society [10,17]. These activities were combined with the
CARE-NMD professional survey to avoid duplication,
with qualitative questions incorporated into the CTSR.
The project resulted in refreshed data from sites already
registered, particularly in the UK where it was integrated
with national network-building and audit activities, and
new registrations by previously non-registered sites.
Discussion
To the best of our knowledge, the CTSR is the largest
and most comprehensive database of neuromuscular
centres in the world. It reduces the need for researchers
to collate their own datasets on neuromuscular centres,
in turn preventing duplication and wasted effort. A key
strength lies in the independence and inclusiveness of
the database, as registration is open to any centre and
the data is held for the benefit of the neuromuscular
community rather than being proprietary to one orga-
nisation. The data currently held in the CTSR is not
exhaustive, and further work is being carried out to
improve geographical and disease coverage. A sizable
cohort of patients does not attend specialist centres
(Kirschner, CARE-NMD unpublished data), while in
some countries a significant proportion of neuromus-
cular centres have not yet registered in the CTSR. For
example, the number of DMD patients accounted for in
the CTSR (373) attending French neuromuscular centres
is much lower than reported in the national mutational
database (3,373) [18]. This may be due in part to the low
number of centres registered in the CTSR from France
(compared, for example, to those reported in the
Orphanet Expert Centres database). In contrast, theMA*
iagnostic techniques
SMA
Muscle biopsy SMA deletion Point mutation Copy number
173 163 116 98
37 37 40 52
13 8 40 42
Table 9 Availability of specific medical specialists for neuromuscular patients
Availability of specific medical specialists
Neurologist Pulmonologist Cardiologist Genetic counselling Physiotherapist
Internal/team member/joint clinics 125 93 82 79 117
External 4 35 46 48 11
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with a mutation in the dystrophin gene detected by any
accredited genetic laboratory in France. Therefore, pa-
tients with other forms of dystrophinopathies, patients
not attending neuromuscular centres and even deceased
patients are accounted for [19,20]. In other countries
such as the UK, the number of DMD patients reported
in the CTSR exceeds the self-report patient registry, and
the coverage of sites in the CTSR is more exhaustive.
CTSR data may therefore be supplemented by other
sources, including national patient registries and other
surveys. However, while acknowledging these limitations,
we believe that CTSR is of significant value to researchers.
The structure of the database allows the selection of
centres according the specific needs of any given project.
When planning a clinical trial, inclusion and exclusion cri-
teria (e.g. age, genetic mutation, steroid and/or ambulatory
status) and willingness to take part restrict the number of
patients that can be recruited at an individual site. For
example, even the most common genetic mutation amen-
able to exon-skipping (skipping of exon 51) is only found
in 13% of patients [21]. Considering these factors, and that
usually at least 5 recruited patients per site are sought,
trial organisers may wish to screen sites to those that see a
certain minimum number of patients – for instance 50 –
with the disease of interest.
Furthermore, the CTSR is flexible and extensible to
serve unforeseen needs, as demonstrated by the addi-
tional utility added to the core database by project-
specific additions for CARE-NMD. This project provides
an example of how the CTSR platform may be extended
and used for innovative research, providing benefits to
the neuromuscular field beyond those initially envisaged.
It also demonstrates how national collaborative efforts
with patient organisations and professional societies can
help ensure record accuracy. The CTSR can help to
determine the level of care available, in addition to feasi-
bility or clinical trial readiness. It is also adaptable to dif-
ferent national and cultural contexts, for example by
displaying different questions based on a site’s countryTable 10 Availability of core specialists in countries with the
Availability of specific
Neurologist Pulmonologis
Internal/team member/joint clinics 125 93
External 4 35of registration. This survey reveals several important fac-
tors about neuromuscular centres and care provision in
different countries. The overall CTSR cohort appears to
be broadly representative of that described in previous
studies. Patients with DMD represent the largest group of
those in the under 18 cohort, whilst those with Myotonic
Dystrophy (DM1) form the largest group of adults. In
2009 Norwood et al. studied prevalence of neuromuscular
diseases in the Northern region in the UK, and found that
the five largest categories of disease were DM1 (28.1%),
B/DMD (~20% taken together), FSHD (10.7%), SMA
(5.1%), and LGMD (6.15%) [22]. The overall population
reported in the CTSR does not match this (17.0% DM1,
37.4% B/DMD, FSHD 9.02%, SMA 14.3%, LGMD 15.3%),
tending to show a higher proportion of childhood-onset
conditions and lower of adult-onset.
We believe this is due to a better representation of
paediatric patients in the CTSR. This could be because
adult patients are more likely to be seen by their family
doctor or a neurologist, rather than attending a specialist
neuromuscular centre. The better representation of chil-
dren in the CTSR (as compared to adults) may also reflect
the relative severity of childhood-onset conditions that
might stimulate significant interest in clinical trial parti-
cipation and registration. By contrast, there may be an
under-diagnosis of mild or late adult-onset conditions
which is reflected in lower CTSR registrations. With the
exception of LGMD, the adult cohort of the CTSR shows
far closer correspondence with Norwood’s data (DM1
27.8%, B/DMD 22.2%, FSHD 15.4%, SMA 8.40%, and
LGMD 22.4%), which is comprehensive in its coverage of
the Northern region of the UK.
However, a recurrent theme from these data is that
the demographics and structure of individual neuromus-
cular centres, as opposed to the overall population, can
vary significantly between different countries. The het-
erogeneous nature of neuromuscular sites is evident
even between countries that might otherwise be consi-
dered similar such as the UK, Germany, and France,
while centre size can vary significantly between countrieslargest number of sites in the CTSR
medical specialists
t Cardiologist Genetic counselling Physiotherapist
82 79 117
46 48 11
Table 11 Transition arrangements for adult care
summary table
Adult care arrangement Number of sites
No transitional arrangement 179
Joint clinic (pediatric and adult neurologist) 54
Regular personal contact between pediatric
and adult neurologist
52
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study in the three countries with the most centres, the size
of centres that report seeing these patients varies drama-
tically: an average of 96 patients per site in the US, 52 in
the UK, and 25 in Germany. Although the US (and
Australia, with an average of 142 patients per site) are per-
haps special geographic cases, the UK and Germany are
not dissimilar and population density would not seem to
explain the difference in average numbers of DMD pa-
tients seen between these two countries. This suggests
that the characteristics of sites are influenced by factors
other than obvious demographic and geographic consi-
derations, such as the structure of national health care
systems. As registration in the CTSR is open to any insti-
tution, it is possible that in some countries sites have
registered that are not neuromuscular reference centres
but still see a small number of neuromuscular patients. As
accreditation of neuromuscular centres is very different
from country to country this would require more in depth
analysis on a national level.
A large number of sites might improve geographic ac-
cessibility to clinical and/or trial expertise. However, it is
also known that the quality of such expertise for rare con-
ditions depends upon regular exposure, in turn implying a
minimally viable number of patients seen at an individual
centre. Furthermore, the additional overheads associated
with conducting clinical trials across many centres with
small patient populations may be prohibitive, and prevent
their participation in research. For these reasons, we sug-
gest that care is taken when planning networks of neuro-
muscular centres to strike a careful balance between aTable 12 Industry enquiries to the CTSR (PR: Patient Registrie
Company Date Type
Prosensa July 2009 Feasibility enquiry
Acceleron September 2009 Feasibility enquiry
Trophos March 2010 Feasibility enquiry
Acceleron June 2010 Feasibility enquiry
Santhera December 2010 Feasibility enquiry
Company X November 2011 Feasibility enquiry (refinement and up
Ultragenyx November 2012 Feasibility enquiry
Eli Lilly May 2013 Feasibility enquiryminimally viable centre size and sufficient provision for
the population to be served.
Regarding the size of centres and their relation to care,
it may be worth examining the practices of rare disease
centres for other conditions such as Cystic Fibrosis (CF).
For example, the 2011 UK CF Registry Annual Data Re-
port lists 32 paediatric and 28 adult specialist centres
(with some centres serving both populations) [19]. Al-
though these too vary in size, it is immediately apparent
that most sites are significantly larger than those serving
neuromuscular conditions. Although this may be in part
explained by the higher prevalence of CF, it provides an
opportunity to investigate the link between centre size
and care, for the primary purpose of the UK CF registry
is to help drive up the standard of clinical care and a
great deal of clinical data is collected in order to allow
this. Whilst mindful of the differences between neuro-
muscular care requirements and those for CF, this may
be a fruitful area for further investigation. Such an ap-
proach has recently been advocated for DMD patient
registries by Scully et al. [23].
Challenges
As with any self-report database, a significant challenge
is in ensuring data accuracy. Site visits by study moni-
tors would be an excellent but expensive way to ensure
data accuracy, and are not feasible in the current setting
with limited resources. Errors can arise from mistakes in
data entry, though this is minimised by validation at the
input stage. As time passes, inaccuracies can occur natu-
rally as information, particularly with regards to patient
cohort and site facilities, becomes outdated. This issue is
mitigated in the CTSR via an update process whereby
sites are contacted at least annually and asked to update
their records. In addition, secondary checks are carried
out upon receipt of individual enquiries: those sites
within the scope of the enquiry are contacted to confirm
that the data held for them is accurate.
This curation of data over time requires time and effort
on the part of the CTSR managers and the sitess)
Disease Registry Geographic coverage
DMD CTSR & PR Europe, USA, Canada
FSHD CTSR only Worldwide
SMA CTSR & PR Europe
DMD CTSR & PR Europe, USA, Canada, Japan
DMD CTSR & PR Europe, USA, Canada
date) DMD CTSR only Worldwide
GNE myopathy CTSR only Worldwide
DMD CTSR & PR Worldwide
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field of a central source of up-to-date data on cohort and
capabilities of a large number of sites outweigh the costs
associated with maintaining this infrastructure. Further-
more, motivation for sites to participate and keep their
data accurate is provided through the potential for them
to be considered for proposed trials, and in recognition of
their collaboration internationally.
Future developments
The CTSR provides a flexible and extensible platform for
the neuromuscular field, and a variety of further develop-
ments are possible. At the simplest these might be minor
extensions with the creation of disease-, country- or
study-specific modules to capture additional information.
Similarly, more sophisticated access permissions could be
created to enable specific categories of users (such as trial
co-ordinators or national curators) with very specific abili-
ties to view or edit particular types of data.
In the longer term, it might be possible to link existing
patient registries to the CTSR, which would enable the
correlation of health information with site information.
This would provide valuable insights into links between
health outcomes and the capabilities of neuromuscular
sites. While there may be logistical and cultural obstacles
to such linkage, it would enable the integration of pa-
tient and centre-level data which would potentially allow
causal links to be identified.
The CTSR platform is also applicable to other disease
areas. For example, within the EU-funded NeurOmics
project the CTSR is currently being extended to cover a
range of neurodegenerative diseases, which will allow
the integration of a large number of new centres [24].
In addition, the CTSR might be used to capture defined
criteria for national or international centres of expertise or
for European Reference Networks for neuromuscular
diseases.
Conclusion
The TREAT-NMD Care and Trial Site Registry is an
example of a field-specific online self-report database for
neuromuscular sites. Although originally envisaged pri-
marily as a tool for clinical trial readiness (as part of a
wider package of translational research tools in the
TREAT-NMD Network), it has proved valuable for pur-
poses beyond those originally considered. The CTSR
platform will continue to be developed by the TREAT-
NMD Alliance. The utility of such a registry of sites has
been demonstrated through numerous enquiries since
its establishment in 2007, and other Rare Disease areas
may wish to consider developing similar initiatives.
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